BGB-900-103
Completed
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Study Overview
Sex:
All
Age: 18 Years / N/A
Study Documents
Study Protocol Statistical Analysis PlanStudy Overview
Sex:
All
Age: 18 Years / N/A